What did we learn from Biogen's CMS slapdown? Data rule
The CMS decision to formally restrict coverage on Aduhelm decisively hammered home the last nail on the Alzheimer’s drug’s commercial coffin. But the muted impact on Biogen’s beaten-down stock was ready evidence that investors had already walked away from the grave.
Shunned by independent experts and a whole swath of physicians who treat Alzheimer’s, longtime skeptic Brian Skorney at Baird now calls the Biogen drug Zombiehelm. And no manner of necromancy can revive it. The first approved drug for Alzheimer’s, what was always considered the Golden Ticket in drug R&D with a multibillion-dollar payout, is commercial waste.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
